Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer

Cell Death and Disease

Volumn 4, Issue 7, 2013, Pages

  Carew, J S ^a   Espitia, C M ^a   Zhao, W ^a   Kelly, K R ^a   Coffey, M ^b   Freeman, J W ^a   Nawrocki, S T ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b ONCOLYTICS BIOTECH INC   (Canada)

Author keywords

Bortezomib; Endoplasmic reticular stress; Pancreatic cancer; Reolysin; Reovirus

Indexed keywords

BORTEZOMIB; BREFELDIN A; CASPASE 4; REOLYSIN; TUNICAMYCIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; X BOX BINDING PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL IMMORTALIZATION; CELL VIABILITY; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; EPITHELIUM CELL; FEMALE; MOUSE; NONHUMAN; ONCOGENE K RAS; PANCREAS CANCER; PRIORITY JOURNAL; REOVIRUS; VIRUS REPLICATION;

EID: 84881061487     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.259     Document Type: Article

References (45)

1. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689.
2. Fearon ER. K-ras gene mutation as a pathogenetic and diagnostic marker in human cancer. J Natl Cancer Inst 1993; 85: 1978-1980.
3. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003; 3: 459-465.
4. Kelly K, Nawrocki S, Mita A, Coffey M, Giles FJ, Mita M. Reovirus-based therapy for cancer. Expert Opin Biol Ther 2009; 9: 817-830.
5. Maitra R, Ghalib MH, Goel S. Reovirus: a targeted therapeutic-progress and potential. Mol Cancer Res 2012; 10: 1514-1525.
6. Norman KL, Lee PW. Reovirus as a novel oncolytic agent. J Clin Invest 2000; 105: 1035-1038.
7. Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM et al. REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res 2010; 16: 5564-5572.
8. Forsyth P, Roldan G, George D, Wallace C, Palmer CA, Morris D et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 2008; 16: 627-632.
9. Harrington KJ, Vile RG, Melcher A, Chester J, Pandha HS. Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev 2010; 21: 91-98.
10. Morris DG, Feng X, Difrancesco LM, Fonseca K, Forsyth PA, Paterson AH et al. REO-001: a phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin(R)) in patients with advanced solid tumors. Invest New Drugs 2012; 31: 696-706.
11. Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 2008; 14: 7127-7137.
12. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282: 1332-1334.
13. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. Embo J 1998; 17: 3351-3362.
14. Nawrocki ST, Carew JS, Dunner K Jr., Boise LH, Chiao PJ, Huang P et al. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 2005; 65: 11510-11519.
15. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K Jr. et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006; 66: 3773-3781.
16. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Dunner K Jr., Huang P et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 2005; 65: 11658-11666.
17. Norman KL, Hirasawa K, Yang AD, Shields MA, Lee PW. Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci USA 2004; 101: 11099-11104.
18. Shmulevitz M, Marcato P, Lee PW. Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer. Oncogene 2005; 24: 7720-7728.
19. Hitomi J, Katayama T, Eguchi Y, Kudo T, Taniguchi M, Koyama Y et al. Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Abeta-induced cell death. J Cell Biol 2004; 165: 347-356.
20. Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007; 67: 1783-1792.
21. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr., Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107: 4907-4916.
22. Rao R, Nalluri S, Fiskus W, Savoie A, Buckley KM, Ha K et al. Role of C/EBP homologous protein (CHOP) in panobinostat-mediated potentiation of bortezomibinduced lethal ER stress in mantle cell lymphoma cells. Clin Cancer Res 2010; 16: 4742-4754.
23. Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 2000; 403: 98-103.
24. Etoh T, Himeno Y, Matsumoto T, Aramaki M, Kawano K, Nishizono A et al. Oncolytic viral therapy for human pancreatic cancer cells by reovirus. Clin Cancer Res 2003; 9: 1218-1223.
25. Hashiro G, Loh PC, Yau JT. The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 1977; 54: 307-315.
26. Pataer A, Hu W, Xiaolin L, Chada S, Roth JA, Hunt KK et al. Adenoviral endoplasmic reticulum-targeted mda-7/interleukin-24 vector enhances human cancer cell killing. Mol Cancer Ther 2008; 7: 2528-2535.
27. Denoyelle C, Abou-Rjaily G, Bezrookove V, Verhaegen M, Johnson TM, Fullen DR et al. Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol 2006; 8: 1053-1063.
28. Hu Y, Lu W, Chen G, Wang P, Chen Z, Zhou Y et al. K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res 2012; 22: 399-412.
29. Lolkema MP, Arkenau HT, Harrington K, Roxburgh P, Morrison R, Roulstone V et al. A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res 2011; 17: 581-588.
30. Pandha HS, Heinemann L, Simpson GR, Melcher A, Prestwich R, Errington F et al. Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res 2009; 15: 6158-6166.
31. Twigger K, Vidal L, White CL, De Bono JS, Bhide S, Coffey M et al. Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res 2008; 14: 912-923.
32. Mahoney DJ, Lefebvre C, Allan K, Brun J, Sanaei CA, Baird S et al. Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death. Cancer Cell 2011; 20: 443-456.
33. McConkey DJ. RAIDDing ER stress for oncolytic viral therapy. Cancer Cell 2011; 20: 416-418.
34. Gorman AM, Healy SJ, Jager R, Samali A. Stress management at the ER: regulators of ER stress-induced apoptosis. Pharmacol Ther 2012; 134: 306-316.
35. Healy SJ, Gorman AM, Mousavi-Shafaei P, Gupta S, Samali A. Targeting the endoplasmic reticulum-stress response as an anticancer strategy. Eur J Pharmacol 2009; 625: 234-246.
36. Qiao J, Wang H, Kottke T, White C, Twigger K, Diaz RM et al. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res 2008; 14: 259-269.
37. Sei S, Mussio JK, Yang QE, Nagashima K, Parchment RE, Coffey MC et al. Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer 2009; 8: 47.
38. Smakman N, van der Bilt JD, van den Wollenberg DJ, Hoeben RC, Borel Rinkes IH, Kranenburg O. Immunosuppression promotes reovirus therapy of colorectal liver metastases. Cancer Gene Ther 2006; 13: 815-818.
39. Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C et al. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res 2012; 18: 2080-2089.
40. Roulstone V, Twigger K, Zaidi S, Pencavel T, Kyula JN, White C et al. Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy. Gene Ther 2012; 20: 521-528.
41. Twigger K, Roulstone V, Kyula J, Karapanagiotou EM, Syrigos KN, Morgan R et al. Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. BMC Cancer 2012; 12: 368.
42. Liao PC, Tan SK, Lieu CH, Jung HK. Involvement of endoplasmic reticulum in paclitaxelinduced apoptosis. J Cell Biochem 2008; 104: 1509-1523.
43. Mandic A, Hansson J, Linder S, Shoshan MC. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 2003; 278: 9100-9106.
44. Zhao S, Wang Y, Cao L, Ouellette MM, Freeman JW. Expression of oncogenic K-ras and loss of Smad4 cooperate to induce the expression of EGFR and to promote invasion of immortalized human pancreas ductal cells. Int J Cancer 2010; 127: 2076-2087.
45. Kelly KR, Espitia CM, Mahalingam D, Oyajobi BO, Coffey M, Giles FJ et al. Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma. Oncogene 2012; 31: 3023-3038.